Overview

Safety of Pre-TURBT Intravesical Instillation of Escalating Doses of TC-3 Gel and MMC in NMIBC Patients

Status:
Completed
Trial end date:
2017-06-01
Target enrollment:
Participant gender:
Summary
A prospective, open label, modified 3+3 dose escalation study. This dose-escalation study is designed to carefully assess the safety of successive cohorts of patients (3 patients/cohort), each cohort treated with a fixed dose of TC-3 and MMC Intravesical instillations.
Phase:
Phase 2
Details
Lead Sponsor:
UroGen Pharma Ltd.
Treatments:
Mitomycin
Mitomycins